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OBJECTIVE—Emerging epidemiological evidence suggests that higher magnesium intake
may reduce diabetes incidence.We aimed to examine the association betweenmagnesium intake
and risk of type 2 diabetes by conducting a meta-analysis of prospective cohort studies.
RESEARCH DESIGN AND METHODS—We conducted a PubMed database search
through January 2011 to identify prospective cohort studies of magnesium intake and risk of
type 2 diabetes. Reference lists of retrieved articles were also reviewed. A random-effects model
was used to compute the summary risk estimates.
RESULTS—Meta-analysis of 13 prospective cohort studies involving 536,318 participants and
24,516 cases detected a significant inverse association between magnesium intake and risk of
type 2 diabetes (relative risk [RR] 0.78 [95% CI 0.73–0.84]). This association was not sub-
stantially modified by geographic region, follow-up length, sex, or family history of type 2
diabetes. A significant inverse association was observed in overweight (BMI $25 kg/m2) but not
in normal-weight individuals (BMI ,25 kg/m2), although test for interaction was not statistically
significant (Pinteraction = 0.13). In the dose-response analysis, the summary RR of type 2 diabetes
for every 100 mg/day increment in magnesium intake was 0.86 (95% CI 0.82–0.89). Sensitivity
analyses restricted to studies with adjustment for cereal fiber intake yielded similar results. Little
evidence of publication bias was observed.
CONCLUSIONS—This meta-analysis provides further evidence supporting that magnesium
intake is significantly inversely associated with risk of type 2 diabetes in a dose-response manner.
Diabetes Care 34:2116–2122, 2011
Type 2 diabetes has been a growingpublic health burden across theworld, particularly in the developing
countries (1). In China, for instance, di-
abetes has reached epidemic proportions,
affecting;92.4 million people aged$20
years (9.7% of the adult population) (2).
Thus, there is an urgent need to develop
primary prevention strategies aimed at con-
trolling this epidemic.
Diet is widely believed to play an
important role in the development of type
2 diabetes (3,4). Magnesium, an impor-
tant component of many foods, such as
whole grains, nuts, and green leafy vege-
tables, is an essential cofactor for enzymes
involved in glucose metabolism (5). Mag-
nesium has received considerable interest
for its potential in improving insulin sen-
sitivity and preventing diabetes (6,7).
A number of prospective cohort studies
(8–19) of magnesium intake and diabe-
tes incidence have been conducted, but
the results are inconsistent. One previ-
ous meta-analysis (14) of eight studies
reported a significant inverse association
between magnesium intake and risk of
type 2 diabetes. Another meta-analysis
(20) of seven studies quantified a dose-
response relationship for this association.
However, it remains unclear whether
overweight, an established risk factor of
type 2 diabetes (21,22), affects the associ-
ation and whether other factors highly
correlated to magnesium intake, such as
cereal fiber (14) and calcium (23), are re-
sponsible for the observed association.
During the past few years, the number
of subsequent primary studies on this
topic has nearly doubled. With mounting
evidence, we conducted a meta-analysis of
prospective cohort studies for the fol-
lowing purposes: 1) to update the epi-
demiologic evidence on the association
between magnesium intake and type 2 di-
abetes; 2) to examine this association ac-
cording to characteristics of study designs
and populations; and 3) to quantify a
dose-response pattern of magnesium in-
take on diabetes risk.
RESEARCH DESIGN AND
METHODS
Literature search
We attempted to report this study in
accordance with the Meta-analysis of
Observational Studies in Epidemiology
guidelines (24) for meta-analyses of ob-
servational studies. We searched the
PubMed database through January 2011,
using the key word magnesium in combi-
nation with diabetes, and examined the
reference lists of the obtained articles. No
restriction was imposed. When necessary,
we contacted authors of original studies
for additional data.
Study selection
Studies were included if they met the
following criteria: the study design was a
prospective cohort study; the exposure of
interest was intake of dietary magnesium
or total magnesium (dietary and supple-
mental); the outcome of interest was in-
cidence of type 2 diabetes; and the risk
estimate of type 2 diabetes related to mag-
nesium intake and associated 95% CI were
reported.
Data extraction and quality
assessment
We used a standardized data collection
form to extract the following informa-
tion: author name; publication year; study
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population, location, and length of follow-
up; number of cases and participants; as-
sessment of exposure and outcome; most
fully adjusted risk estimate from multivari-
ablemodel for the highest versus the lowest
category of magnesium intake with corre-
sponding 95% CI; and statistical adjust-
ment for the main confounding factors of
interest. In one study (8), we used data
from themultivariablemodel with full con-
trol for potential confounders but not for
insulin and glucose because magnesium
plays an important role in insulin action
and glucose homeostasis (5), and adjust-
ment for insulin and glucose, therefore,
could represent overadjustment for variables
on the causal pathway. Two authors (J.-Y.D.
and L.-Q.Q.) independently performed the
literature search, study selection, and data
extraction. Any disagreements were re-
solved by discussion.
Statistical analysis
The relative risk (RR) was used as the
common measure of association across
studies, and the hazard ratio and inci-
dence rate ratio were considered directly
as RR. Homogeneity test was performed
with the use of Q statistic at the P, 0.10
level of significance. We also calculated
the I2 statistic, a quantitative measure of
inconsistency across studies (25). Because
of the presence of heterogeneity across
studies, a random-effects model, which
considered both within- and between-
study variation, was used to compute
the summary risk estimate.
Prespecified subgroup analyses ac-
cording to geographic region, length of
follow-up, sex, family history of diabetes,
and BMI were performed to examine the
impacts of these factors on the association.
To test the robustness of the association, we
also performed sensitivity analyses restricted
to studies on dietary magnesium only and
studies with further adjustment for cereal
fiber intake. In addition, we examined the
influence of a single study on the summary
risk estimate by omitting one study in each
turn.
We next quantified a potential linear
dose-response relationship of magnesium
intake to diabetes risk because most in-
dividual studies have detected a significant
linear trend. We first calculated an RR for
every 100mg/day increment inmagnesium
intake for each study based on the method
proposed by Greenland and Longnecker
(26). These RRs across studies were then
combined to obtain a summary estimate.
Potential publication bias was as-
sessed by Begg rank correlation test and
Egger linear regression test (27,28). All
analyses were performed using STATA
version 11.0 (StataCorp, College Station,
TX). All statistical tests were two-sided and
P, 0.05 was considered statistically signif-
icant, except where otherwise specified.
RESULTS
Study characteristics
We identified 13 prospective cohort stud-
ies (8–19) of magnesium intake and
risk of type 2 diabetes—one article (11)
included two separate cohort studies—
involving 536,318 participants and 24,516
incident cases. All studies reported type 2
diabetes as the primary outcome except
one study (17) that did not specify diabetes
type (the great majority of participants had
type 2 diabetes). Characteristics of the se-
lected studies are presented in Table 1.
The 13 prospective cohort studies were
published between 1999 and 2010. Of
them, eight studies were conducted in
the United States, three in Asia, one in
Europe, and one in Australia. The number
of cases diagnosed in the primary studies
ranged from 330 to 8,587, and the number
of participants ranged from 4,497 to
85,060. Both men and women were in-
cluded in seven studies, one study consisted
of men only, and five studies consisted of
women only. Of the studies, nine reported
results on dietary magnesium intake, two
(11) on total (dietary and supplemental)
magnesium intake, and two (12,17) on
both dietary and total magnesium intake.
Intake of supplemental magnesium was
assessed from use ofmagnesium ormulti-
vitamin supplements; however, dietary
magnesium accounted for the majority
of total magnesium intake.
The mean length of follow-up ranged
from 4 to 20 years. Most studies used
validated food-frequency questionnaires
in dietary assessment. Diabetes ascertain-
ment was largely based on self-reports of
physician diagnosis, but the majority of
cases were confirmed in validation stud-
ies. The major adjusted confounders in-
cluded age, BMI, physical activity, total
energy intake, alcohol consumption,
smoking, education, and family history of
diabetes. Adjusted dietary confounders
were varied across individual studies,
whereas cereal fiber intake was adjusted
for in five studies (9,11,14,17).
Main analysis
The multivariable-adjusted RRs of type 2
diabetes for each study and all studies
combined for the highest versus the lowest
category of magnesium intake are shown
in Figure 1. Of the 13 selected studies,
9 found a statistically significant inverse
association betweenmagnesium intake and
diabetes risk. The summary RR of type 2
diabetes was 0.78 (95% CI 0.73–0.84),
comparing the highest with the lowest
category of magnesium intake. Substantial
heterogeneity was observed across studies
(Pheterogeneity = 0.04, I
2 = 42.4%).
Subgroup and sensitivity analyses
Table 2 presents the results of subgroup
analyses stratified by characteristics of
study designs and populations. Overall,
the inverse association between magne-
sium intake and risk of type 2 diabetes
was not substantially modified by geo-
graphic region, follow-up length, sex, or
family history of diabetes. Notably, the
observed inverse association was more
pronounced among participants with
BMI $25 kg/m2 (RR 0.73 [95% CI
0.66–0.81]), and there was little evidence
of heterogeneity (Pheterogeneity = 0.21, I
2 =
28.1%). However, no association was ob-
served among those with BMI,25 kg/m2
(RR 1.09 [0.76–1.56]).
To test the robustness of our findings,
we conducted sensitivity analyses. Re-
stricting analysis to studies of dietary mag-
nesium intake yielded an RR of 0.80 (95%
CI 0.70–0.86; n = 11). Restricting analysis
to studies that controlled for cereal fiber
yielded an RR of 0.74 (0.68–0.80; n = 5).
Further analyses investigating the influ-
ence of a single study on the overall risk
estimate by omitting one study at each
turn yielded a narrow range of RRs from
0.77 (0.72–0.82) to 0.79 (0.74–0.85). In
addition, no single study substantially con-
tributed to the heterogeneity across studies.
Dose-response analysis
In the dose-response analysis of the 13
primary studies, the summary RR of type
2 diabetes for every 100 mg/day increment
in magnesium intake was 0.86 (95% CI
0.82–0.89), with evidence of heterogeneity
among studies (Pheterogeneity = 0.02, I
2 =
48.4%).
Publication bias
There was little evidence of publication
bias with regard to magnesium intake in
relation to risk of type 2 diabetes, as in-
dicated by Begg rank correlation test (P =
0.99) and Egger linear regression test
(P = 0.95).
CONCLUSIONS—In the past decade,
the role of magnesium in development of
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type 2 diabetes has been increasingly rec-
ognized. The present updatedmeta-analysis
of 13 prospective cohort studies involv-
ing 536,318 participants and 24,516
cases determined a significant inverse as-
sociation between magnesium intake and
risk of type 2 diabetes in a dose-response
manner.
Substantial heterogeneity was ob-
served across studies, whichwas expected
given the between-study variation, such
as inconsistent data collecting methods,
various nutrient databases, and different
ethnic populations. In our subgroup anal-
yses, the results were not substantially
affected by geographic region, follow-up
length, sex, or family history of diabetes,
whereas the association tended to be stron-
ger in overweight than in normal-weight
individuals. The absence of heterogeneity
in the stratified analyses by BMI indicated
that BMI may, at least partially, contribute
to the overall between-study variation.
More important, BMImay serve as an effect
modifier of the magnesium and diabetes
association. All included cohort studies
have adjusted for BMI, but only six studies
(11,12,17–19) have assessed the impacts
of BMI on the association between magne-
sium intake and diabetes risk. Among
them, three studies (12,17,18) found
more pronounced associations in over-
weight individuals than in normal-weight
ones, yet only one (12) reached statistical
significance in interaction tests. In our
stratified analyses, the effect of BMI on
the association was apparent, although
the test for interaction was not statistically
significant (Pinteraction = 0.13), which was
likely the result of insufficient statistical
power. Of note, it is plausible that high
magnesium intake may have greater ef-
fects on improving insulin sensitivity in
overweight individuals who are prone to
insulin resistance (12). In this regard, waist
circumference and waist-to-hip ratio,
which are suggested to be better predictors
of insulin resistance than BMI (29), may
have more pronounced effects on the mag-
nesium and diabetes association.
Because magnesium intake highly
correlated to other healthy lifestyle and
dietary factors, such as cereal fiber and
calcium intakes, it is difficult to isolate the
effect of magnesium intake on diabetes
risk from other factors. Consequently, the
potential influences of these factors de-
serve consideration while interpreting the
results. Higher cereal fiber intake has
been shown to be associated with a re-
duced diabetes risk (14). In our analysis
restricted to five studies (9,11,14,17) with
control for cereal fiber intake, the inverse
association between magnesium intake
and diabetes risk persisted and remained
statistically significant. In addition, limited
Table 2—Subgroup analyses relating magnesium to type 2 diabetes by characteristics of study designs and populations
Group Number of studies RR (95% CI) P Pheterogeneity I
2 (%) Pinteraction
Total 13 0.78 (0.73–0.84) ,0.001 0.04 42.4
Geographic area 0.64
U.S. 8 0.77 (0.71–0.83) ,0.001 0.04 49.9
Asia 3 0.81 (0.71–0.91) 0.001 0.53 0
Duration (years) 0.93
#6 7 0.79 (0.73–0.85) ,0.001 0.05 48.9
.6 6 0.78 (0.75–0.82) ,0.001 0.12 40.2
Sex 0.95
Men 5 0.77 (0.73–0.81) ,0.001 0.85 0
Women 9 0.76 (0.70–0.83) ,0.001 0.06 47.1
Family history of diabetes 0.83
Yes 4 0.73 (0.62–0.85) ,0.001 0.42 0
No 4 0.71 (0.62–0.80) ,0.001 0.31 15.7
BMI (kg/m2) 0.13
,25 3 1.09 (0.76–1.56) 0.76 0.12 52.9
$25 6 0.73 (0.66–0.81) ,0.001 0.21 28.1
Figure 1—Forest plot of prospective cohort studies examining magnesium intake and risk of type
2 diabetes. M, male; F, female.
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evidence suggests calcium intake may
play a role in preventing diabetes (23).
However, in the Black Women’s Health
Study (13) that mutually adjusted for mag-
nesium and calcium, the association be-
tween calcium intake and risk of type 2
diabetes disappeared, whereas an inverse
association with magnesium intake re-
mained. Moreover, physical activity (11,15)
and smoking (15,18), two important and
modifiable risk factors for diabetes (30,31),
appeared not to have appreciable impacts
on the association. Taken together, exist-
ing evidence to date from observational co-
hort studies supports an independent,
protective role ofmagnesium intake against
type 2 diabetes.
Indeed, experimental and metabolic
studies have provided convincing evidence
in support of direct effects of magnesium
intake on insulin resistance and type 2
diabetes. Intracellular magnesium defi-
ciency may result in disorders of tyrosine
kinase activity during insulin signaling
and glucose-induced insulin secretion,
leading to impaired insulin sensitivity in
muscle cells and adipocytes (32,33). In
animal studies,magnesium supplementation
has been shown to protect against fructose-
induced insulin resistance (6) and reduce
the development of diabetes in rat models
(7). Furthermore, evidence from ran-
domized controlled studies suggests that
magnesium supplementation may exert
beneficial effects on glucose control in
patients with type 2 diabetes (34) and im-
prove insulin sensitivity in nondiabetic
subjects (35–37).
Our findings confirmed results from
previous meta-analyses (14,20). With the
accumulative evidence, we were able to
enhance the precision of the risk estimates
and perform subgroup analyses to ex-
plore sources of heterogeneity, thereby
increasing the clinical relevance of our
findings (38). Also, all included studies
used a prospective cohort design, which
minimized the likelihood of recall and se-
lection biases. In addition, the presence of
dose-response relationship strengthened
the association of magnesium intake
with risk of type 2 diabetes.
Several limitations should be ac-
knowledged. First, observational studies
cannot establish causal association, and
residual confounding remains a concern.
A wide range of potential confounders,
including demographic and lifestyle factors,
were adjusted for in the primary studies,
whereas dietary factorswerenot sufficiently
considered. Therefore, we could not fully
exclude the possibility that unmeasured or
inaccurately measured dietary factors are
responsible for the observed association.
Second, misclassification bias may have
weakened the strength of the association.
Because dietary assessment was based on
self-administered questionnaires, mis-
classification of dietary magnesium in-
take is inevitable. Misclassification of
diabetes cases is also likely to occur
given that diabetes ascertainments inmost
studies were based on self-reports. Few
studies (11,15,17,19) repeated dietary as-
sessment during the follow-up period,
which may also result in misclassification.
Third, we could not completely rule out
the influences of changes in diet on the
risk estimate in those with subclinical
diabetes at baseline. Sensitivity analyses
that excluded cases diagnosed within the
initial several years of follow-up would
help examine these influences and
achieve more reliable results, but they
were performed in few studies (15). Fi-
nally, publication bias could affect results
of meta-analyses. However, minimal evi-
dence of this bias was detected in our
meta-analysis.
Our findings have implications for
further research and are of public health
significance. Apart from adequate control
for potential confounders, particularly
dietary factors, subsequent cohort studies
of magnesium intake and type 2 diabetes
should take the potential effect modifica-
tion by BMI into consideration. Individual-
level meta-analyses (39) with more power
to detect effect modification than study-
level meta-analyses may also be pursued.
To date, large scale, randomized, placebo-
controlled trials, which provide the
strongest evidence for establishing a
causal relation (40), have not been carried
out to directly evaluate the effect of mag-
nesium on diabetes incidence. Given the
compelling evidence from the observa-
tional studies, such trials are anticipated
to draw definitive conclusions. As for pub-
lic health, increased consumption of
magnesium-rich foods, such as whole
grains, nuts, and green leafy vegetables,
may bring considerable benefits in diabetes
prevention, especially in those at high risk.
In conclusion, the presentmeta-analysis
of prospective cohort studies provides
further evidence in support of a significant
inverse association between magnesium
intake and risk of type 2 diabetes, consis-
tent with a dose-response relationship.
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